These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28057482)

  • 41. Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic. Preface.
    Expert Group Members
    Food Chem Toxicol; 2010 Jan; 48 Suppl 1():S1. PubMed ID: 20113849
    [No Abstract]   [Full Text] [Related]  

  • 42. Quantitative structure-activity relationships and COMPACT analysis of a series of food mutagens.
    Lewis DF; Ioannides C; Walker R; Parke DV
    Food Addit Contam; 1995; 12(5):715-23. PubMed ID: 8522037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simple and alpha,beta-unsaturated aldehydes: correct prediction of genotoxic activity through structure-activity relationship models.
    Benigni R; Conti L; Crebelli R; Rodomonte A; Vari' MR
    Environ Mol Mutagen; 2005 Dec; 46(4):268-80. PubMed ID: 15991240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of in silico models for prediction of mutagenicity.
    Bakhtyari NG; Raitano G; Benfenati E; Martin T; Young D
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2013; 31(1):45-66. PubMed ID: 23534394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk assessment of genotoxic mutagens with thresholds: a brief introduction.
    Kirsch-Volders M; Gonzalez L; Carmichael P; Kirkland D
    Mutat Res; 2009 Aug; 678(2):72-5. PubMed ID: 19442759
    [No Abstract]   [Full Text] [Related]  

  • 48. A QSAR model for predicting mutagenicity of nitronaphthalenes and methylnitronaphthalenes.
    Zhang Z; Niu J; Zhi X
    Bull Environ Contam Toxicol; 2008 Nov; 81(5):498-502. PubMed ID: 18777149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
    Brusick DJ
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product.
    Dow LK; Hansen MM; Pack BW; Page TJ; Baertschi SW
    J Pharm Sci; 2013 May; 102(5):1404-18. PubMed ID: 23436613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of control groups in mutagenicity studies: matching biological and statistical relevance.
    Hauschke D; Hothorn T; Schäfer J
    Altern Lab Anim; 2003 Jun; 31 Suppl 1():65-75. PubMed ID: 15595901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutagenic probability estimation of chemical compounds by a novel molecular electrophilicity vector and support vector machine.
    Zheng M; Liu Z; Xue C; Zhu W; Chen K; Luo X; Jiang H
    Bioinformatics; 2006 Sep; 22(17):2099-106. PubMed ID: 16837526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A urinous tale.
    Fitzpatrick M
    Lancet; 2003 Mar; 361(9359):792. PubMed ID: 12620777
    [No Abstract]   [Full Text] [Related]  

  • 54. In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey.
    Dobo KL; Greene N; Fred C; Glowienke S; Harvey JS; Hasselgren C; Jolly R; Kenyon MO; Munzner JB; Muster W; Neft R; Reddy MV; White AT; Weiner S
    Regul Toxicol Pharmacol; 2012 Apr; 62(3):449-55. PubMed ID: 22321701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Automatic knowledge extraction from chemical structures: the case of mutagenicity prediction.
    Ferrari T; Cattaneo D; Gini G; Golbamaki Bakhtyari N; Manganaro A; Benfenati E
    SAR QSAR Environ Res; 2013; 24(5):365-83. PubMed ID: 23710765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sales of contaminated animal drugs halted.
    Henkel J
    FDA Consum; 1999; 33(5):34. PubMed ID: 10522171
    [No Abstract]   [Full Text] [Related]  

  • 57. Recent advances in trace analysis of pharmaceutical genotoxic impurities.
    Liu DQ; Sun M; Kord AS
    J Pharm Biomed Anal; 2010 Apr; 51(5):999-1014. PubMed ID: 20022442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico prediction of the mutagenicity of nitroaromatic compounds using a novel two-QSAR approach.
    Ding YL; Lyu YC; Leong MK
    Toxicol In Vitro; 2017 Apr; 40():102-114. PubMed ID: 28027902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
    Bercu JP; Hoffman WP; Lee C; Ness DK
    Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.